Marker Therapeutics Files 8-K
Ticker: MRKR · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
Marker Therapeutics filed an 8-K on 10/6/25. Standard reporting.
AI Summary
Marker Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting other events and financial statements. The company, formerly known as TAPIMMUNE INC. and GENEMAX CORP, is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is important for investors to stay updated on the company's status.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain any significant new risks or material events.
Key Players & Entities
- Marker Therapeutics, Inc. (company) — Registrant
- TAPIMMUNE INC. (company) — Former company name
- GENEMAX CORP (company) — Former company name
- 20251006 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of October 6, 2025.
What is Marker Therapeutics, Inc.'s former company name?
Marker Therapeutics, Inc. was formerly known as TAPIMMUNE INC. and GENEMAX CORP.
In which state is Marker Therapeutics, Inc. incorporated?
Marker Therapeutics, Inc. is incorporated in Delaware.
What is the principal business address of Marker Therapeutics, Inc.?
The principal business address is 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021.
What is the IRS Employer Identification Number for Marker Therapeutics, Inc.?
The IRS Employer Identification Number for Marker Therapeutics, Inc. is 45-4497941.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2025-10-06 07:30:37
Key Financial Figures
- $0.001 — h registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
Filing Documents
- tm2527906d1_8k.htm (8-K) — 25KB
- tm2527906d1_ex99-1.htm (EX-99.1) — 15KB
- tm2527906d1_ex99-1img001.jpg (GRAPHIC) — 16KB
- 0001104659-25-096935.txt ( ) — 231KB
- mrkr-20251006.xsd (EX-101.SCH) — 3KB
- mrkr-20251006_lab.xml (EX-101.LAB) — 33KB
- mrkr-20251006_pre.xml (EX-101.PRE) — 22KB
- tm2527906d1_8k_htm.xml (XML) — 4KB
01. Other Information
Item 8.01. Other Information On October 6, 2025, Marker Therapeutics, Inc. (" Marke r" or the " Company ") issued a press release announcing that the first patient had been treated in the Company's Off-the-Shelf (" OTS ") Program evaluating Marker's Multi-Antigen Recognizing (MAR)-T cell therapy. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated October 6, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: October 6, 2025 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer